Dr. Tap on the Rise of Precision Medicine in Sarcoma

Partner | Cancer Centers | <b>Memorial Sloan Kettering Cancer Center </b>

William D. Tap, MD, discusses the rise of precision medicine in sarcoma.

William D. Tap, MD, chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses the rise of precision medicine in sarcoma.

The treatment landscape of sarcoma is rapidly evolving with regard to advances in science, technology, and biology, says Tap.

For example, the explosion of immunotherapy options has been transformative across multiple tumor types, Tap explains. Other areas of significant cancer research include epigenetics, cellular signaling, and DNA damage response patterns.

Sarcoma is a prime target to implement precision medicine, as the disease is associated with numerous genomic aberrations, Tap says.

Moreover, the field is moving toward tailoring treatments to individual disease subtypes based on genomic and epigenetic abnormalities rather than treating all patients with sarcoma with the same one-size-fits-all approach, concludes Tap.